Opportunities in Healthcare
DAVID SEMPLE: So I think it was a very interesting time to come to China. There's clearly been a lot of stimulus that has gone on in the context of an economy which is naturally slowing down. So, the question is, How’s that is working? And, How are the disruptions in various sectors working? Which is really important when you analyze that. Because [there’s] a lot of change. So, for instance, I spent a lot of time in the healthcare chain, with pharmaceutical companies, trying to figure out how and how quickly we're moving from a relatively dysfunctional delivery system for medical services and drugs into a much better, cheaper, and more innovative environment for healthcare in China. And that goes from everything from the delivery of medical information and diagnosis through telemedicine into the development of pharmaceuticals, in particular. Things along the lines of biosimilars. Truly innovative work has been done there. I think that's important to understand. But it also raises some really nice opportunities in terms of investment. However, with some high stock-specific risks in those companies. So, we're busy working hard, trying to figure out which companies are the winners out of this and trying to figure out how exactly we would access them.
Impact of Coronavirus
SEMPLE: And I think there's also a lot of concern about China and China's slowing down and if there are dislocations, let's put it that way, in the Chinese economy. And our view is always, yeah there are. Yes, it's slowing down, yes there are dislocations, but these are not fundamental. These are not going to derail the whole story. If you can pick your spots, pick your companies, pick your sectors, pick your industries, then you can do very well, as we have done over the years in in our Chinese investments. So that's one aspect of it.
Now, one thing that's relatively recent that comes into this whole equation for emerging markets is obviously what's happened with Wuhan and the coronavirus there. Look, it's a fast moving situation. There's a lot of emotive language: “ground zero”, people in hazmat suits. I think this is same but different from SARS episode, which obviously, I lived through. I think it's ... The incidents of this particular coronavirus is higher, so the infection rate appears to be higher. However, there's no doubt that it will slow down economic activity. They're much more on top of it this time, the Chinese. Whether they are on top of it completely is a question mark, but they're much more “executive”, let's call it that way, about what's happening. They're not really trying to hide it under the … , sweep it under the carpet. So that's going to be a big issue as we look into first quarter numbers and when, or if and when, we see the peak in this, then I think we might get a very rapid rebound in riskier markets. And that's what emerging markets still are.
Ping An Good Doctor: The Future of Healthcare
SEMPLE: So one of the companies that we own, and I caught up with when I was in Shanghai is a spinoff from the Ping An Group. Ping An is one of the largest insurers in China. And this company's called Ping An Good Doctor. What Ping An Good Doctor does is telemedicine. So effectively, the issue in the past in China is that if you wanted to see a doctor, you really had to go to hospitals. There's very little sort of family practitioners. You'd go to the hospital; you have to wait a couple of hours typically for your appointment. It might be something relatively simple and you get some medicine for it, you get the prescription, you get that filled but it's only for a month and then you have to do it all over again. You might live two or three hours away from the hospital and then two or three hours in the hospital. I mean, this is a big problem in terms of people actually getting access to it. And some cases, there just isn't enough specialist doctors, so a lot of ailments go un-prescribed, undiagnosed. For instance, the instance of gastric cancer is probably a lot higher in China than the numbers will tell us.
So what this company does is it effectively provides artificial intelligence enhanced that helps the doctors diagnose what is going on with the patient. Now at this stage, a lot of these diagnoses are free. The first 15 minutes is effectively free. As they prove the concept, as they bear the brand name out there, and as they get the data to be used to make the systems even better going forward, and then we're moving into a situation where China's increasingly liberalizing the delivery of prescriptions online. So, a lot of that takes away that dysfunctionality of what's going on in the regular medical consultation market in China.
- - - - - - - - - - - - - - - - - - - - - - - - -
The views and opinions expressed are those of the speaker and are current as of the video’s posting date. Video commentaries are general in nature and should not be construed as investment advice. Opinions are subject to change with market conditions. All performance information is historical and is not a guarantee of future results. For more information about VanEck Funds, VanEck Vectors ETFs or fund performance, visit vaneck.com. Any discussion of specific securities mentioned in the video commentaries is neither an offer to sell nor a solicitation to buy these securities. Fund holdings will vary. All indices mentioned are measures of common market sectors and performance. It is not possible to invest directly in an index. Information on holdings, performance and indices can be found at vaneck.com.
All performance information is historical and is not a guarantee of future results. This is not an offer to buy or sell any of the securities mentioned herein. Fund holdings will vary. For a complete list of holdings in the Fund, please visit vaneck.com.
You can lose money by investing in the Fund. Any investment in the Fund should be part of an overall investment program, not a complete program. The Fund is subject to the risks associated with its investments in Chinese issuers, communication services sectors, direct investments, emerging market securities which tends to be more volatile and less liquid than securities traded in developed countries, foreign currency transactions, foreign securities, other investment companies, Stock Connect, management, market, operational, sectors and small- and medium-capitalization companies risks . The Fund’s investments in foreign securities involve risks related to adverse political and economic developments unique to a country or a region, currency fluctuations or controls, and the possibility of arbitrary action by foreign governments, or political, economic or social instability.
Investing involves substantial risk and high volatility, including possible loss of principal. An investor should consider the investment objective, risks, charges and expenses of a Fund carefully before investing. To obtain a prospectus and summary prospectus, which contain this and other information, call 800.826.2333 or visit vaneck.com. Please read the prospectus and summary prospectus carefully before investing.
No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission of Van Eck Securities Corporation. © Van Eck Securities Corporation.
Van Eck Securities Corporation, Distributor
666 Third Avenue, New York, NY 10017